Answers are grounded in this paper and cite their sources.
In oncology clinical trials, on-treatment biopsy samples are taken to confirm the mode of action of new molecules, among other reasons. Yet, the time point of sample collection is typically scheduled according to 'Expert Best Guess'. We have developed an approach integrating digital pathology and mathematical modelling to provide clinical teams with quantitative information to support this decision. Using digitised biopsies from an ongoing clinical trial as the input to an agent-based mathematical model, we have quantitatively optimised and validated the model demonstrating that it accurately recapitulates observed biopsy samples. Furthermore, the validated model can be used to predict the dynamics of simulated biopsies, with applications from protocol design for phase 1-2 studies to the conception of combination therapies, to personalised healthcare.
No takes yet. Share an insight, caveat, or question.
Lucy Hutchinson (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: